News & Events

In the news

Our very first webinar is now streaming!

"Cytotoxicity testing solutions for ADCC, CDC and apoptosis"

You missed the webinar and would like to catch up or you’re looking like to watch the session again? The talk is now streaming on this page.

Webinar – 1st october 2020

"Cytotoxicity testing solutions for ADCC, CDC and apoptosis"

Come to discover our solutions to characterize your mAb products through a presentation of our Cytotoxicity assay (ADCC, CDC, apoptosis) during a webinar presented by Alexis Rossignol, PhD project manager and Bio assay specialist at Clean Cells.

Covid-19 information

Let us know if we can support you

Clean Cells, specialized in the detection of biological contaminant is always committed to contribute to the development of innovative drugs.

Covid-19 information

Clean Cells maintains its usual level of activity

In the context of the coronavirus (CoviD-19) epidemic, Clean Cells' teams are closely monitoring the evolution of the situation in order to guarantee business continuity but also to protect the safety and health of our employees.

BE Vaccines is now NAOBIOS

After joining Clean Cells on March 1st, 2019, BE Vaccines has been renamed NAOBIOS.

Created originally by the Valneva Group (ex-Vivalis) in 2005, then taken over by the Indian company Biological E in 2013 with the aim of stepping up the technical development of viral vaccines, BE VACCINES joined CLEAN CELLS on March 1st, 2019.

Press Release

CLEAN CELLS acquires BE VACCINES and demonstrates its development ambitions

On March 1st, 2019, Clean Cells acquired BE Vaccines, a French subsidiary of the Indian Pharmaceutical Company Biological E. Limited (BE).

Clean Cells’ Events

Meet with Clean Cells

In the first quarter, join the Clean Cells’ team at: PHAGE FUTURES CONGRESS, CarT CONGRESS EU, BACTERIOPHAGE THERAPY SUMMIT...

Clean Cells accelerates its developments

Clean Cells accelerates its developments with ArchiMed

Clean Cells opened its capital to ArchiMed to support its growth strategy in the biopharmaceutical sector.

ut luctus dictum ut eget ut venenatis justo